Peptide-Drug Conjugates (PDCs) Emerge as Promising Targeted Cancer Therapies
Peptide-drug conjugates (PDCs) are emerging as a novel class of cancer therapeutics, offering potential advantages over antibody-drug conjugates (ADCs) due to their smaller size and rapid internalization.
Oryzon's Vafidemstat Receives FDA Support for Phase III Trial in Borderline Personality Disorder
Oryzon Genomics has received positive feedback from the FDA regarding its Phase II meeting for vafidemstat in Borderline Personality Disorder (BPD).
ReAlta Life Sciences Doses First Patient in Phase 2 aGvHD Trial with RLS-0071
ReAlta Life Sciences has initiated a Phase 2 clinical trial of RLS-0071 for steroid-refractory acute graft-versus-host disease (aGvHD).
Active Breaks Show Promise in Boosting Academic Performance for Children with and without ADHD
A new study, Break4Brain, investigates the impact of physical activity (PA) on academic achievement in children, focusing on those with and without ADHD.
AAVantgarde Bio Doses First Patient in Phase 1/2 Trial of AAVB-081 for Usher Syndrome Type 1B
AAVantgarde Bio has dosed the first patient in its Phase 1/2 LUCE-1 trial, evaluating AAVB-081 gene therapy for Usher Syndrome Type 1B (USH1B).
LSU LCMC Health Cancer Center Spearheads Advances in Cancer Research and Equitable Care
The LSU LCMC Health Cancer Center is focusing on community-based research to address cancer treatment and prevention in Louisiana.
Silexion's LODER Shows Promise in Non-Resectable Pancreatic Cancer
Silexion Therapeutics' LODER demonstrated a 56% objective response rate in patients with non-resectable pancreatic cancer bearing KRAS G12D/V mutations.
Clene to Meet with FDA to Discuss Accelerated Approval for CNM-Au8 in ALS
Clene will meet with the FDA to discuss accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis (ALS).
Lipidor AB Initiates Phase III Trial of AKP02G2 for Psoriasis Treatment
Lipidor AB has enrolled the first patient in its Phase III clinical trial evaluating AKP02G2, a topical spray for mild to moderate psoriasis.
RHEACELL's Allo-APZ2-CVU Receives FDA Approval for Phase 3 Trial in Refractory Chronic Venous Ulcers
RHEACELL's allo-APZ2-CVU, a first-in-class stem cell therapy, has received FDA approval for a Phase 3 trial (NCT06489028) to treat chronic venous ulcers (CVU).
Inebilizumab Shows Promise in Myasthenia Gravis, Phase 3 Data Suggests
Phase 3 MINT trial data indicates inebilizumab significantly improves Myasthenia Gravis Activities of Daily Living (MG-ADL) scores compared to placebo.
MesoPher Immunotherapy Shows Promise in Resected Pancreatic Cancer
A phase 2 trial of MesoPher, a dendritic cell-based immunotherapy, demonstrated a 64% 2-year recurrence-free survival rate in patients with resected pancreatic cancer.
Donanemab Approved in US for Early Alzheimer's Treatment, UK Approval Uncertain
The FDA approved donanemab in July 2024 for early symptomatic Alzheimer's, including mild cognitive impairment and mild dementia.
Bristol Myers Squibb and 2seventy bio Discontinue Enrollment in Phase 3 KarMMa-9 Trial for Abecma in Newly Diagnosed Multiple Myeloma
Bristol Myers Squibb and 2seventy bio halted enrollment in the Phase 3 KarMMa-9 trial evaluating Abecma (idecabtagene vicleucel) plus lenalidomide maintenance versus lenalidomide alone in newly diagnosed multiple myeloma (NDMM) patients.
Surufatinib and Toripalimab Combination Shows Promise in Extensive-Stage Small Cell Lung Cancer
A phase Ib/II study reveals that surufatinib combined with toripalimab, etoposide, and cisplatin demonstrates a high objective response rate (ORR) of 97.1% in ES-SCLC patients.
Shionogi Submits Zuranolone NDA in Japan for Major Depressive Disorder
Shionogi has submitted a New Drug Application (NDA) in Japan for zuranolone, targeting the treatment of major depressive disorder (MDD).
Dupixent Approved in China as First Biologic for COPD Patients
The NMPA in China approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD with raised blood eosinophils.
PAS-004 Shows Favorable Safety and Early Efficacy in MAPK-Driven Solid Tumors
PAS-004, a next-generation MEK inhibitor, demonstrates a tolerable safety profile in early phase 1 trial cohorts of patients with advanced MAPK-driven cancers.
Estrogen's Role in Tumor Growth and Immune Suppression Unveiled, Offering New Therapeutic Avenues
Estrogen has been found to promote tumor growth in estrogen receptor-negative breast cancers and other cancers like melanoma and colon cancer by suppressing the immune system.
Third-Line ART in Ethiopia Shows 76.9% Virologic Suppression Rate
A study in Addis Ababa found a 76.9% virologic suppression rate at 6 months among HIV patients on third-line antiretroviral therapy (ART).